CH667013A5 - Pharmazeutisches mittel zur lokalen therapie der psoriasis. - Google Patents

Pharmazeutisches mittel zur lokalen therapie der psoriasis. Download PDF

Info

Publication number: CH667013A5
Authority: CH; Switzerland
Prior art keywords: acid; glucocorticoid; active ingredient; antipsoriatic; free
Prior art date: 1984-10-17

Application number

CH4254/85A

Other languages

German (de)

English (en)

Inventor

Josef Dr Mueller

Hans-Ulrich Petereit

Original Assignee

Roehm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-17

Filing date

1985-10-02

Publication date

1988-09-15

1985-10-02 Application filed by Roehm Gmbh filed Critical Roehm Gmbh

1988-09-15 Publication of CH667013A5 publication Critical patent/CH667013A5/de

Links

201000004681 Psoriasis Diseases 0.000 title claims description 15
238000002560 therapeutic procedure Methods 0.000 title claims description 15
239000008177 pharmaceutical agent Substances 0.000 title claims description 9
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 30
239000004480 active ingredient Substances 0.000 claims description 27
239000012790 adhesive layer Substances 0.000 claims description 19
230000002682 anti-psoriatic effect Effects 0.000 claims description 17
239000006185 dispersion Substances 0.000 claims description 16
239000000853 adhesive Substances 0.000 claims description 15
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 15
229960004889 salicylic acid Drugs 0.000 claims description 15
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 14
NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims description 14
229960002311 dithranol Drugs 0.000 claims description 13
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 12
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
239000004202 carbamide Substances 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 7
229960000458 allantoin Drugs 0.000 claims description 7
FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 6
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 6
235000010323 ascorbic acid Nutrition 0.000 claims description 6
229960005070 ascorbic acid Drugs 0.000 claims description 6
239000011668 ascorbic acid Substances 0.000 claims description 6
KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 6
239000001530 fumaric acid Substances 0.000 claims description 6
239000010410 layer Substances 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
229940124597 therapeutic agent Drugs 0.000 claims description 6
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
229960002703 undecylenic acid Drugs 0.000 claims description 6
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
239000003638 chemical reducing agent Substances 0.000 claims description 5
238000009826 distribution Methods 0.000 claims description 5
229930002330 retinoic acid Natural products 0.000 claims description 5
239000011975 tartaric acid Substances 0.000 claims description 5
235000002906 tartaric acid Nutrition 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
239000008139 complexing agent Substances 0.000 claims description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
235000018417 cysteine Nutrition 0.000 claims description 3
229920000642 polymer Polymers 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
239000004310 lactic acid Substances 0.000 claims description 2
235000014655 lactic acid Nutrition 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 claims 1
229960002598 fumaric acid Drugs 0.000 claims 1
238000000034 method Methods 0.000 claims 1
229910052700 potassium Inorganic materials 0.000 claims 1
239000011591 potassium Substances 0.000 claims 1
230000001070 adhesive effect Effects 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
-1 polyethylene Polymers 0.000 description 7
239000000203 mixture Substances 0.000 description 6
239000008213 purified water Substances 0.000 description 6
239000011269 tar Substances 0.000 description 5
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
239000002245 particle Substances 0.000 description 4
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 4
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 3
GWZMWHWAWHPNHN-UHFFFAOYSA-N 2-hydroxypropyl prop-2-enoate Chemical compound CC(O)COC(=O)C=C GWZMWHWAWHPNHN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
239000003862 glucocorticoid Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
229940037128 systemic glucocorticoids Drugs 0.000 description 3
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000005250 alkyl acrylate group Chemical group 0.000 description 2
ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
239000012935 ammoniumperoxodisulfate Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
ZZBWSNKBZKPGAK-UHFFFAOYSA-N chrysophanol-9-anthrone Chemical compound C1=CC=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O ZZBWSNKBZKPGAK-UHFFFAOYSA-N 0.000 description 2
239000011280 coal tar Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000011888 foil Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
TXPYHRFTMYVSLD-UHFFFAOYSA-N 2,3,4-tris(2-methylpropyl)phenol Chemical compound CC(C)CC1=CC=C(O)C(CC(C)C)=C1CC(C)C TXPYHRFTMYVSLD-UHFFFAOYSA-N 0.000 description 1
OWHSTLLOZWTNTQ-UHFFFAOYSA-N 2-ethylhexyl 2-sulfanylacetate Chemical compound CCCCC(CC)COC(=O)CS OWHSTLLOZWTNTQ-UHFFFAOYSA-N 0.000 description 1
DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
238000007303 Carboni reaction Methods 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
229940124091 Keratolytic Drugs 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241001092473 Quillaja Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
238000006887 Ullmann reaction Methods 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
YUTJCNNFTOIOGT-UHFFFAOYSA-N anthracene-1,8,9-triol Chemical compound C1=CC(O)=C2C(O)=C3C(O)=CC=CC3=CC2=C1 YUTJCNNFTOIOGT-UHFFFAOYSA-N 0.000 description 1
150000004056 anthraquinones Chemical class 0.000 description 1
229940030999 antipsoriatics Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical class C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
201000000421 erythematosquamous dermatosis Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000004744 fabric Substances 0.000 description 1
229960004511 fludroxycortide Drugs 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
230000036074 healthy skin Effects 0.000 description 1
230000001530 keratinolytic effect Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
238000010327 methods by industry Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000006353 oxyethylene group Chemical group 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000011505 plaster Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
HEZHYQDYRPUXNJ-UHFFFAOYSA-L potassium dithionite Chemical compound [K+].[K+].[O-]S(=O)S([O-])=O HEZHYQDYRPUXNJ-UHFFFAOYSA-L 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000009419 refurbishment Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000003079 shale oil Substances 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Adhesive Tapes (AREA)

CH4254/85A 1984-10-17 1985-10-02 Pharmazeutisches mittel zur lokalen therapie der psoriasis. CH667013A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19843438005 DE3438005A1 (de)	1984-10-17	1984-10-17	Pharmazeutisches mittel zur lokalen therapie der psoriasis

Publications (1)

Publication Number	Publication Date
CH667013A5 true CH667013A5 (de)	1988-09-15

Family

ID=6248085

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH4254/85A CH667013A5 (de)	1984-10-17	1985-10-02	Pharmazeutisches mittel zur lokalen therapie der psoriasis.

Country Status (9)

Country	Link
BE (1)	BE903471A (da)
CH (1)	CH667013A5 (da)
DE (1)	DE3438005A1 (da)
DK (1)	DK473885A (da)
FR (1)	FR2571619B1 (da)
GB (1)	GB2165453B (da)
IT (1)	IT1185827B (da)
NL (1)	NL8502842A (da)
SE (1)	SE461251B (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19833177A1 (de) *	1998-07-23	2000-01-27	Labtec Gmbh	Pflasterabdeckung nach Reizung

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL97012A0 (en) *	1990-01-30	1992-03-29	Gist Brocades Nv	Topical preparations for treating human nails
DE4006628A1 (de) *	1990-03-06	1990-11-22	Bernd Dr Med Ditter	Verfahren zur oertlichen daueranwendung von antiallergischen, entzuendungshemmenden und juckreizstillenden hautmitteln
ITMI20042111A1 (it) *	2004-11-04	2005-02-04	Biofarmitalia Spa	Cerotto contenenti una sostanza scelta tra i catrami aventi caratteristiche riducenti in dermatologia
EP1923059A1 (en) *	2004-11-04	2008-05-21	BIOFARMITALIA S.p.A.	Patch containing a substance selected from tars having reducing characteristics in dermatology
WO2006119540A1 (en) *	2005-05-11	2006-11-16	Jenny Nicolopoulos	Preparation for treating psoriasis
WO2008013493A1 (en)	2006-07-25	2008-01-31	Iss Immune System Stimulation Ab	Topical treatment of warts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB950380A (en) *	1962-02-27	1964-02-26	Perry Bowell Overseas Ltd	Pharmaceutical products for the treatment of skin diseases
IE31985B1 (en) *	1967-03-29	1973-03-07	Lilly Co Eli	Medicated adhesive tape
FR2047874A6 (da) *	1969-06-10	1971-03-19	Nouvel Lucien
US3896789A (en) *	1974-06-10	1975-07-29	Riker Laboratories Inc	Retinoic acid dipensing pressure sensitive dermotological tape
JPS5758615A (en) *	1980-09-26	1982-04-08	Nippon Soda Co Ltd	Film agnent and its preparation
JPS6059207B2 (ja) *	1981-03-13	1985-12-24	日東電工株式会社	複合製剤の製法
GB2105990B (en) *	1981-08-27	1985-06-19	Nitto Electric Ind Co	Adhesive skin patches
JPS5852216A (ja) *	1981-09-22	1983-03-28	Daikyo Yakuhin Kogyo Kk	貼付剤
LU83710A1 (fr) *	1981-10-23	1983-06-07	Cird	Matrice de diffusion polymerique a base d'anthraline ou de l'un de ses derives et son application dans le traitement des maladies de la peau
ATE42901T1 (de) *	1984-03-05	1989-05-15	Nitto Denko Corp	Haftendes arzneimittelpraeparat fuer perkutane absorption.

1984
- 1984-10-17 DE DE19843438005 patent/DE3438005A1/de not_active Withdrawn
1985
- 1985-09-25 FR FR8514177A patent/FR2571619B1/fr not_active Expired
- 1985-10-02 CH CH4254/85A patent/CH667013A5/de not_active IP Right Cessation
- 1985-10-14 IT IT67871/85A patent/IT1185827B/it active
- 1985-10-16 SE SE8504796A patent/SE461251B/sv not_active IP Right Cessation
- 1985-10-16 DK DK473885A patent/DK473885A/da not_active Application Discontinuation
- 1985-10-17 NL NL8502842A patent/NL8502842A/nl not_active Application Discontinuation
- 1985-10-17 BE BE0/215747A patent/BE903471A/fr not_active IP Right Cessation
- 1985-10-17 GB GB8525673A patent/GB2165453B/en not_active Expired

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19833177A1 (de) *	1998-07-23	2000-01-27	Labtec Gmbh	Pflasterabdeckung nach Reizung

Also Published As

Publication number	Publication date
IT8567871A0 (it)	1985-10-14
BE903471A (fr)	1986-02-17
DK473885A (da)	1986-04-18
SE8504796D0 (sv)	1985-10-16
GB8525673D0 (en)	1985-11-20
GB2165453B (en)	1989-05-24
SE8504796L (sv)	1986-04-18
SE461251B (sv)	1990-01-29
NL8502842A (nl)	1986-05-16
FR2571619B1 (fr)	1988-10-14
IT1185827B (it)	1987-11-18
FR2571619A1 (fr)	1986-04-18
DK473885D0 (da)	1985-10-16
DE3438005A1 (de)	1986-04-17
GB2165453A (en)	1986-04-16

Legal Events

Date	Code	Title	Description
1992-06-30	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE69801893T2 (de)	2002-04-25	Ölige Pflaster mit NA-Diclofenac zur äusseren Anwendung
DE4241874C2 (de)	1997-03-06	Medizinisches Pflaster für die perkutane Verabreichung des Wirkstoffs Ketoprofen
DE60216634T2 (de)	2007-09-27	Gel mit mindestens einem retinoid und benzoylperoxid
DE69029804T2 (de)	1997-09-04	VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
DE3111550C2 (de)	1986-06-05	Antiphlogistisches analgetisches Pflaster
EP1467706B1 (de)	2007-03-14	Dermales applikationssystem für aminolävulinsäure-derivate
DE69715049T2 (de)	2003-04-03	Tranilast enthaltendes externum und verfahren zu dessen herstellung
DE2207294C2 (de)	1982-12-02	Topische Salbengrundlage
DE19922662C1 (de)	2000-12-28	Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE69108683T2 (de)	1995-10-05	Zubereitung zur transdermalen Verabreichung von Arzneimitteln.
DE69815263T2 (de)	2004-05-06	Stabile zubereitung auf basis von acetylsalicylsäure zur äusseren anwendung
EP0186019A2 (de)	1986-07-02	Wirkstoffpflaster
EP0439180A2 (de)	1991-07-31	Transdermales therapeutisches System mit dem Wirkstoff Tulobuterol
EP0376067A2 (de)	1990-07-04	Transdermales therapeutisches System mit Physostigmin als wirksamen Bestandteil und Verfahren zu seiner Herstellung
CH672598A5 (da)	1989-12-15
DD290582A5 (de)	1991-06-06	Verfahren zur herstellung eines transdermalen therapeutischen systems zur verabreichung von physostigmin an die haut
DD266506A5 (de)	1989-04-05	Verfahren zur herstellung einer pharmazeutischen band-zusammensetzung
DE69521734T2 (de)	2001-11-08	Perkutane Zubereitung enthaltend Tulobuterol
CH643456A5 (de)	1984-06-15	Pharmazeutische zubereitung.
DE68909026T2 (de)	1994-04-14	Topische Anwendung eines Medikaments in einem Bindemittel.
DE3411225C2 (da)	1991-11-07
DE2818827C2 (de)	1983-10-27	Mittel zur Behandlung von Psoriasis
DE3880754T2 (de)	1993-10-07	Perkutanes Präparat mit kontrollierter Abgabe.
DE60011686T2 (de)	2005-06-30	Mit Betamethasone und Hyaluronsaüre behandeltes dünnes adhäsives Pflaster für die Behandlung von Psoriasis, Dermatitis, und Dermatosis
DE3438005A1 (de)	1986-04-17	Pharmazeutisches mittel zur lokalen therapie der psoriasis

CH667013A5 - Pharmazeutisches mittel zur lokalen therapie der psoriasis. - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=6248085

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (6)

Family Cites Families (10)

Cited By (1)

Also Published As

Similar Documents

Legal Events